Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.
| Revenue (Most Recent Fiscal Year) | $2.76B |
| Net Income (Most Recent Fiscal Year) | $-1.03B |
| PE Ratio (Current Year Earnings Estimate) | 172.51 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 5.73 |
| Price to Sales Ratio (Trailing 12 Months) | 4.17 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.94 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.49 |
| Pre-Tax Margin (Trailing 12 Months) | -34.51% |
| Net Margin (Trailing 12 Months) | -34.19% |
| Return on Equity (Trailing 12 Months) | -1.75% |
| Return on Assets (Trailing 12 Months) | -0.76% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.89 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.94 |
| Inventory Turnover (Trailing 12 Months) | 5.52 |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.98 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.22 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.23 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 189.32M |
| Free Float | 187.05M |
| Market Capitalization | $12.25B |
| Average Volume (Last 20 Days) | 2.12M |
| Beta (Past 60 Months) | 1.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |